Key facts
- It has raised $42.3M; the latest was Later Stage VC ($28.1M) in Oct 2025.
- Notable investors include YuanBio Venture Capital, Orinno Capital, Sichuan Venture Capital, Chengdu New Economy Venture Capital, Guoyuan Innovating Investment — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Hyperway Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Hyperway Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hyperway Pharmaceuticals
Developer of targeted innovative drugs focused on oncology, pain management and central nervous system diseases. The company operates a brain-penetrating drug development platform and manages the full R&D chain from target screening to registration, enabling faster development of differentiated therapies driven by clinical needs and original innovation.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2019
- Employees
- 100
- Website
- hyperwaypharma.com/
- Ownership
- Privately Held (backing)
Hyperway Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hyperway Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hyperway Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.